WINTON GROUP Ltd purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 7,654 shares of the company’s stock, valued at approximately $763,000.
Several other institutional investors have also recently made changes to their positions in CELC. EverSource Wealth Advisors LLC increased its stake in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the period. US Bancorp DE increased its stake in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after buying an additional 1,167 shares during the period. Ogorek Anthony Joseph NY ADV boosted its position in Celcuity by 19.7% during the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after purchasing an additional 109 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Celcuity by 211.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after purchasing an additional 3,766 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.
Celcuity Price Performance
Shares of NASDAQ CELC opened at $88.24 on Thursday. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The company has a market cap of $4.30 billion, a PE ratio of -22.63 and a beta of 0.10. The business has a 50-day simple moving average of $120.79 and a two-hundred day simple moving average of $111.44. Celcuity, Inc. has a fifty-two week low of $11.27 and a fifty-two week high of $151.02.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the company. Leerink Partners set a $155.00 price objective on Celcuity in a research report on Tuesday, June 2nd. Wolfe Research reaffirmed an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research report on Thursday, May 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $157.00 price objective on shares of Celcuity in a research report on Friday, May 15th. Finally, Macquarie Infrastructure set a $160.00 price objective on Celcuity in a research report on Thursday, May 28th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $152.09.
View Our Latest Stock Report on Celcuity
Insider Activity
In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the sale, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This represents a 27.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 37,000 shares of company stock valued at $5,111,950. Corporate insiders own 13.33% of the company’s stock.
About Celcuity
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
See Also
- Five stocks we like better than Celcuity
- As Shares Fall, Analyst Are Boosting their Broadcom Price Targets
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
